for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Thermo Fisher Scientific Inc.

TMO.N

Latest Trade

380.25USD

Change

-2.02(-0.53%)

Volume

405,468

Today's Range

379.79

 - 

385.69

52 Week Range

250.29

 - 

386.55

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
382.27
Open
381.13
Volume
405,468
3M AVG Volume
33.23
Today's High
385.69
Today's Low
379.79
52 Week High
386.55
52 Week Low
250.29
Shares Out (MIL)
394.95
Market Cap (MIL)
150,978.00
Forward P/E
30.21
Dividend (Yield %)
0.23

Next Event

Thermo Fisher Scientific Inc to Discuss Cell Culture & Upstream Processing/Continuous Processing at BioProcess International Europe

Latest Developments

More

FDA Grants Breakthrough Device Designation To Thermo Fisher's Oncomine Precision Assay

Thermo Fisher Entered Term Loan Credit Agreement

Genetron Holdings Says Entered Strategic Partnership Agreement With Thermo Fisher

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. It offers its products and services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines. Analytical Instruments segment provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory. Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Services segment offers products and solutions needed for the laboratory.

Industry

Medical Equipment & Supplies

Contact Info

168 3rd Ave

WALTHAM, MA

02451-7551

United States

+1.781.6221000

https://www.thermofisher.com/

Executive Leadership

Marc N. Casper

Chairman of the Board, President, Chief Executive Officer

Stephen Williamson

Chief Financial Officer, Senior Vice President

Mark P. Stevenson

Chief Operating Officer, Executive Vice President

Michel Lagarde

Executive Vice President

Michael A. Boxer

Senior Vice President, General Counsel

Key Stats

1.76 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

20.9K

2018

24.4K

2019

25.5K

2020(E)

25.9K
EPS (USD)

2017

9.490

2018

11.120

2019

12.350

2020(E)

12.655
Price To Earnings (TTM)
41.63
Price To Sales (TTM)
5.89
Price To Book (MRQ)
5.29
Price To Cash Flow (TTM)
25.19
Total Debt To Equity (MRQ)
69.92
LT Debt To Equity (MRQ)
67.34
Return on Investment (TTM)
7.19
Return on Equity (TTM)
6.47

Latest News

Latest News

BRIEF-Thermo Fisher Scientific - Estimates Both Reported, Organic Revenue Growth Will Be About 10% For Q2

* THERMO FISHER SCIENTIFIC - ESTIMATES BOTH REPORTED, ORGANIC REVENUE GROWTH WILL BE ABOUT 10% FOR Q2

Major Qiagen shareholder demands higher bid from Thermo Fisher - source

The coronavirus pandemic has boosted Qiagen's prospects and a takeover by Thermo Fisher no longer makes sense unless the offer is increased substantially, one of the German genetic test maker's top ten shareholders told Reuters on Friday.

Major Qiagen shareholder opposes Thermo Fisher takeover - source

The coronavirus pandemic has boosted Qiagen's prospects as a standalone company and a takeover by Thermo Fisher no longer makes sense unless the offer is increased substantially, one of the German genetic test maker's top ten shareholders told Reuters on Friday.

BRIEF-Thermo Fisher Scientific Launches New MAS Omni Infectious Disease Quality Controls

* THERMO FISHER SCIENTIFIC LAUNCHES NEW MAS OMNI INFECTIOUS DISEASE QUALITY CONTROLS Source text for Eikon: Further company coverage:

BRIEF-Schrödinger Collaborates With Thermo Fisher To Expand Structure-Based Drug Discovery

* SCHRÖDINGER ANNOUNCES STRATEGIC COLLABORATION WITH THERMO FISHER SCIENTIFIC TO EXPAND STRUCTURE-BASED DRUG DISCOVERY TO NOVEL TARGETS USING CRYO-EM

BRIEF-Thermo Fisher, Daiichi Sankyo To Co-Develop Global Companion Diagnostic For Non-Small Cell Lung Cancer

* THERMO FISHER SCIENTIFIC AND DAIICHI SANKYO TO CO-DEVELOP GLOBAL COMPANION DIAGNOSTIC FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER

BRIEF-FDA Grants Breakthrough Device Designation To Thermo Fisher's Oncomine Precision Assay

* U.S. FDA - HAS GRANTED BREAKTHROUGH DEVICE DESIGNATION TO THERMO FISHER SCIENTIFIC'S ONCOMINE PRECISION ASSAY Source text for Eikon: Further company coverage:

BRIEF-Thermo Fisher Entered Term Loan Credit Agreement

* THERMO FISHER - ON JUNE 5, ENTERED TERM LOAN CREDIT AGREEMENT REPLACING EUR3.0 BILLION BRIDGE LOAN FACILITY WITH EUR3.0 BILLION SENIOR UNSECURED 1-YEAR TERM FACILITY

BRIEF-Genetron Holdings Says Entered Strategic Partnership Agreement With Thermo Fisher

* GENETRON HOLDINGS LIMITED SAYS ENTERED STRATEGIC PARTNERSHIP AGREEMENT WITH THERMO FISHER SCIENTIFIC WITH PLANS TO BUILD ON SEQUENCER GENETRON S5 Source text for Eikon: Further company coverage:

BRIEF-PharmAbcine Execute An Agreement With Thermo Fisher For Development, Manufacturing Of Its Next-Generation Immune Checkpoint Blockade

* PHARMABCINE EXECUTE AN AGREEMENT WITH THERMO FISHER FOR THE DEVELOPMENT AND MANUFACTURING OF ITS NEXT-GENERATION IMMUNE CHECKPOINT BLOCKADE, PMC-309 FOR PHASE I Source text for Eikon: Further company coverage:

BRIEF-Thermo Fisher To Co-Develop A Global Companion Diagnostic For Low-Grade Glioma With Agios Pharmaceuticals

* THERMO FISHER SCIENTIFIC - TO CO-DEVELOP A GLOBAL COMPANION DIAGNOSTIC FOR LOW-GRADE GLIOMA WITH AGIOS PHARMACEUTICALS

BRIEF-Thermo Fisher Scientific And CSL Enter Strategic Partnership To Provide Best-In-Class Pharma Services

* THERMO FISHER SCIENTIFIC AND CSL ENTER STRATEGIC PARTNERSHIP TO PROVIDE BEST-IN-CLASS PHARMA SERVICES

BRIEF-CSL Enters Partnership With Thermo Fisher Scientific

* ENTERED INTO A STRATEGIC PARTNERSHIP WITH THERMO FISHER SCIENTIFIC

BRIEF-Thermo Fisher Scientific Declares Quarterly Dividend

* SETS QUARTERLY CASH DIVIDEND OF $0.22PER SHARE Source text for Eikon: Further company coverage:

BRIEF-Thermo Fisher Receives Contract From U.S. Govt To Provide Transport Media For Covid-19 Sample Collection

* THERMO FISHER - RECEIVED CONTRACT FROM U.S. GOVERNMENT TO PROVIDE HIGHLY SPECIALIZED VIRAL TRANSPORT MEDIA FOR COVID-19 SAMPLE COLLECTION

BRIEF-Thermo Fisher Scientific Publishes Offer Document For Voluntary Tender Offer For All Ordinary Shares Of Qiagen N.V.

* THERMO FISHER SCIENTIFIC PUBLISHES OFFER DOCUMENT FOR VOLUNTARY TENDER OFFER FOR ALL ORDINARY SHARES OF QIAGEN N.V.

Thermo Fisher launches 39 euros/share bid for Qiagen

U.S. life science tools company Thermo Fisher on Monday launched its agreed $11.5 billion takeover offer for Qiagen, calling on investors of the German genetic testing specialist to tender their shares.

BRIEF-Thermo Fisher Publishes Voluntary Tender Offer For All Ordinary Shares Of Qiagen N.V.

* THERMO FISHER SCIENTIFIC PUBLISHES OFFER DOCUMENT FOR VOLUNTARY TENDER OFFER FOR ALL ORDINARY SHARES OF QIAGEN N.V.

BRIEF-Thermo Fisher Says Expected Range For Q2 Organic Revenue Growth To Between Flat And Negative 10%

* THERMO FISHER SCIENTIFIC INC - UPDATED ITS EXPECTED RANGE FOR Q2 ORGANIC REVENUE GROWTH TO BETWEEN FLAT AND NEGATIVE 10% Source: (https://bit.ly/2LlPT6V) Further company coverage:

BRIEF-Thermo Fisher Scientific Response To Covid-19 Expands To Include New Serology Test

* THERMO FISHER SCIENTIFIC RESPONSE TO COVID-19 EXPANDS TO INCLUDE NEW SEROLOGY TEST

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up